MaxiVAX SA, a Swiss biotech developing anti-cancer vaccines, and Minaris Regenerative Medicine GmbH, a CDMO for the cell and gene therapies, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.   The manufacturing agreement includes process development for scale-up and technology transfer with the goal of supplying Phase 2 and 3 clinical studies in the EU and then in the U.S....